Compare Futu Holdings Ltd (FUTU) vs Summit Therapeutics Inc (SMMT) Price & Performance

FUTU trades at $98.2, up 0.07% on the day, with a bullish technical signal but mixed earnings history including a Q1 2026 miss. The company shows strong fundamentals with 2025 revenue of $22.85B, net income margin of 49.62%, and robust cash flow. However, multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The outlook is clouded by legal risks despite solid profitability and analyst support (58% buy ratings). Investment opportunity hinges on resolution of regulatory allegations, while key risks include potential financial penalties and reputational damage from ongoing litigation.

Summit Therapeutics (SMMT) trades at $14.51, down 6.21% today, with a bearish technical outlook despite positive clinical trial results for its lung cancer drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, but maintains strong analyst support with 14 buy ratings and a $15.57 consensus price target. Recent developments include the $105 million divestiture of ridinilazole to Biossil and upcoming Q2 2026 earnings.

SMMT presents a high-risk, binary investment case centered on ivonescimab's commercial potential. While analyst sentiment is bullish and recent trial data is promising, the company's significant losses, cash burn, and single-asset focus pose substantial risks. The stock's volatility and concentrated ownership create potential for sharp moves around clinical and regulatory catalysts.